LISATA THERAPEUTICS, INC. — Director's Dealing 2019

Jan 16, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2019-01-14

Reporting Person: Mazzo David J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-14	Common Stock	A	47000	—	Acquired	157706	Direct
2019-01-14	Common Stock	F	6301	—	Disposed	151405	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-14	Stock Options (Right to Buy)	$4.95	A	71000	Acquired	2029-01-14	Common Stock (71000.0)	Direct

Footnotes

F1: Represents 47,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.

F2: Includes 51,900 unvested restricted stock awards.

F3: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.